Patents by Inventor Robert Hontz

Robert Hontz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-Layer Hybrid Edge Termination for III-N Power Devices
    Publication number: 20230030549
    Abstract: A hybrid edge termination structure and method of forming the same. The hybrid edge termination structure in accordance with the invention is based on a junction termination extension (JTE) architecture, but includes an additional Layer of guard ring (GR) structures to further implement the implantation of dopants into the structure. The hybrid edge termination structure of the invention has a three-Layer structure, with a top Layer and a bottom Layer each having a constant dopant concentration in the lateral direction, and a middle Layer consisting of a plurality of spatially defined alternating regions that exhibit the electrical properties of either the top or bottom layer. By including the second layer, a discretized varying charge profile can be obtained that approximates the varying charge profile obtained using tapered edge termination but with easier manufacturing and lower cost.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 2, 2023
    Applicant: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Travis J. Anderson, Mona A. Ebrish, Andrew D. Koehler, Alan G. Jacobs, Matthew A. Porter, Karl D. Hobart, Prakash Pandey, Tolen Michael Nelson, Daniel G. Georgiev, Raghav Khanna, Michael Robert Hontz
  • CONTROLLED RELEASE NANOPARTICULATE COMPOSITIONS
    Publication number: 20130011447
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Controlled-release nanoparticulate compositions
    Patent number: 8293277
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: October 23, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Glipizide compositions
    Patent number: 8236352
    Abstract: The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: H. William Bosch, Niels P. Ryde, Rajeev A. Jain, Jon Swanson, Robert Hontz, John G. Devane, Kenneth Ian Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
    Publication number: 20110300210
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: May 6, 2011
    Publication date: December 8, 2011
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
    Publication number: 20090297619
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 3, 2009
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
  • Nanoparticulate anticonvulsant and immunosuppressive compositions
    Publication number: 20080248123
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 9, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary Liversidge
  • Controlled release nanoparticulate compositions
    Publication number: 20080124393
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 29, 2008
    Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd
  • Nanoparticulate anticonvulsant and immunosuppressive compositions
    Publication number: 20070048378
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: November 3, 2006
    Publication date: March 1, 2007
    Inventors: Jon Swanson, Rajeev Jain, Robert Hontz, John Devane, Kenneth Cumming, Maurice Joseph Clancy, Janet Codd
  • CONTROLLED-RELEASE NANOPARTICULATE COMPOSITIONS
    Publication number: 20020012675
    Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
    Type: Application
    Filed: June 22, 1999
    Publication date: January 31, 2002
    Inventors: RAJEEV A. JAIN, JON SWANSON, ROBERT HONTZ, JOHN DEVANE, KENNETH IAIN CUMMING, MAURICE JOSEPH ANTHONY CLANCY, JANET ELIZABETH CODD